FDA panel puts haemostatic agent/dressing reclassification on hold
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has recommended that the agency postpone a decision to downclassify absorbable haemostatic agents and dressings until the staff develops a guidance document that adequately covers this group of products.